
These Factors Are Contributing to Gilead Sciences’ Weak Outlook
Gilead Sciences’ (GILD) revenue fell 7% and 13% in 2016 and 9M17, respectively. The fall was due to lower product sales. Both antiviral products and other products recorded declines in both the periods.